New prostate cancer drug trial opens for chinese men
NCT ID NCT07339267
First seen Jan 22, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This early-stage study tests a new drug called ASP5541 in about 12 Chinese men whose prostate cancer has spread. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to check the drug's safety and how it moves through the body. Men can stay on treatment until their cancer worsens or their doctor says to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.